2-alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: Their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A2B receptor

Journal of Medicinal Chemistry

Volumn 44, Issue 2, 2001, Pages 170-179

  Harada, H ^a   Asano, O ^a   Hoshino, Y ^a   Yoshikawa, S ^a   Matsukura, M ^a   Kabasawa, Y ^a   Niijima, J ^a   Kotake, Y ^a   Watanabe, N ^a   Kawata, T ^a   Inoue, T ^a   Horizoe, T ^a   Yasuda, N ^a   Minami, H ^a   Nagata, K ^a   Murakami, M ^a   Nagaoka, J ^a   Kobayashi, S ^a   Tanaka, I ^a   Abe, S ^a  

^a EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 [6 AMINO 8 (3 FLUORO 4 METHOXYPHENYL) 9 METHYL 9H 2 PURINYL] 1 ETHYNYL] 1 CYCLOPENTANOL HYDROCHLORIDE; 2 (2 HYDROXYETHYL) 1 [3 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL)ACRYLOYL]PIPERIDINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 5,9 DIHYDRO 6 METHOXYCARBONYL 9 METHYL 2 PHENYL 1,2,4 TRIAZOLO[5,1 A][2,7]NAPHTHYRIDINE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; 9 METHYLADENINE DERIVATIVE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR; ANTIDIABETIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHINESE HAMSTER; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; GENETIC TRANSFECTION; GLUCONEOGENESIS; HYPOGLYCEMIA; IC 50; LIVER CELL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY CELL; STRUCTURE ACTIVITY RELATION;

ADENINE; ALKYNES; ANIMALS; CELLS, CULTURED; CHO CELLS; CRICETINAE; DIABETES MELLITUS; GLUCOSE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MICE; RADIOLIGAND ASSAY; RATS; RECEPTORS, PURINERGIC P1; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 0035905833     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990499b     Document Type: Article

References (53)

1. Adenosine receptors: New opportunities for future drugs
2. 1 adenosine receptor
3. 1 adenosine receptor
4. 2 receptor with physiological constitutive activity
5. 2 Receptor
6. 2. Adenosine receptor subtype
7. 2B receptor from human brain
8. 3 adenosine receptor
9. 3 adenosine receptor
10. Pathogenesis of NIDDM: A balanced overview
11. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM)
12. Stimulation of glycogenolysis and vasoconstriction by adenosine and adenosine analogues in the perfused liver
13. Adenosine reversal of in vivo hepatic responsiveness to insulin
14. Effects of an adenosine-receptor antagonist on insulin-resistance in soleus muscle from obese zucker rats
15. Characterization of the adenosine receptor modulating insulin action in rat skeletal muscle
16. 1 adenosine receptor antagonism improves glucose tolerance in zucker rats
17. Tissue-specific effects of in vivo adenosine receptor blockage on glucose uptake in zucker rats
18. Is muscle the major site of insulin resistance in type 2 (non-insulin-dependent) diabetes mellitus?
19. Adenosine receptor antagonists: Structure and potential therapeutic applications
20. Novel 1,3-dialkytxanthine derivatives having high potency as antagonists at human A2B adenosine receptors
21. Modification of the 5′ position of purine nucleosides. 2. Synthesis and some cardiovascular properties of adenosine-5′-(N-substituted)carboxamides
22. A functional screening of adenosine analogues at the adenosine A2B receptor: A search for potent agonists
23. 1 adenosine receptor
24. 2 receptors
25. 2 receptor agonists with potent antihypertensive effects
26. 2 receptor agonists with potent antihypertensive effects
27. 2 adenosine receptor agonists with potent Antihypertensive activity
28. 2 adenosine receptors
29. 2 receptor agonists with potent inhibitory activity on platelet aggregation
30. 2A adenosine receptor agonists
31. 2 receptor ligands
32. 2 receptor agonists in a series of N-alkylated 2-aminoadenosines
33. 2 adenosine receptor
34. 2 adenosine receptor
35. New substituted 9-alkylpurines as adenosine receptor ligands
36. 2B4) cells
37. 1 receptor antagonist
38. 2 antagonists
39. 2 antagonist, (E)-l,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine
40. 3 adenosine receptor antagonists
41. Breeding of mice strains for diabetes mellitus
42. Preparation of 2,5-diamino-4,6-dichloropyrimidine
43. Potential purine antagonists. IV. Synthesis of some 9-methyl-6-substituted-purines
44. Synthesis of paraxanthine analogues (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-Position: Structure-activity relationships at adenosine receptors
45. Palladium-catalyzed cross-coupling of 2-iodoadenosine with terminal alkynes: Synthesis and biological activities of 2-alkynyladenosines
46. 2B-adenosine receptor
47. 2B adenosine receptor in NIH 3T3 fibroblasts
48. Oral hypoglycemic agents: An update of sulfonylureas
49. Biguanides and NIDDM
50. 50) of an enzymatic reaction